AIRLINK 81.10 Increased By ▲ 2.55 (3.25%)
BOP 4.82 Increased By ▲ 0.05 (1.05%)
CNERGY 4.09 Decreased By ▼ -0.07 (-1.68%)
DFML 37.98 Decreased By ▼ -1.31 (-3.33%)
DGKC 93.00 Decreased By ▼ -2.65 (-2.77%)
FCCL 23.84 Decreased By ▼ -0.32 (-1.32%)
FFBL 32.00 Decreased By ▼ -0.77 (-2.35%)
FFL 9.24 Decreased By ▼ -0.13 (-1.39%)
GGL 10.06 Decreased By ▼ -0.09 (-0.89%)
HASCOL 6.65 Increased By ▲ 0.11 (1.68%)
HBL 113.00 Increased By ▲ 3.50 (3.2%)
HUBC 145.70 Increased By ▲ 0.69 (0.48%)
HUMNL 10.54 Decreased By ▼ -0.19 (-1.77%)
KEL 4.62 Decreased By ▼ -0.11 (-2.33%)
KOSM 4.12 Decreased By ▼ -0.14 (-3.29%)
MLCF 38.25 Decreased By ▼ -1.15 (-2.92%)
OGDC 131.70 Increased By ▲ 2.45 (1.9%)
PAEL 24.89 Decreased By ▼ -0.98 (-3.79%)
PIBTL 6.25 Decreased By ▼ -0.09 (-1.42%)
PPL 120.00 Decreased By ▼ -2.70 (-2.2%)
PRL 23.90 Decreased By ▼ -0.45 (-1.85%)
PTC 12.10 Decreased By ▼ -0.89 (-6.85%)
SEARL 59.95 Decreased By ▼ -1.23 (-2.01%)
SNGP 65.50 Increased By ▲ 0.30 (0.46%)
SSGC 10.15 Increased By ▲ 0.26 (2.63%)
TELE 7.85 Decreased By ▼ -0.01 (-0.13%)
TPLP 9.87 Increased By ▲ 0.02 (0.2%)
TRG 64.45 Decreased By ▼ -0.05 (-0.08%)
UNITY 26.90 Decreased By ▼ -0.09 (-0.33%)
WTL 1.33 Increased By ▲ 0.01 (0.76%)
BR100 8,052 Increased By 75.9 (0.95%)
BR30 25,581 Decreased By -21.4 (-0.08%)
KSE100 76,707 Increased By 498.6 (0.65%)
KSE30 24,698 Increased By 260.2 (1.06%)

Novartis AG said on Tuesday it would make its generic pre-filled epinephrine shots immediately available in local pharmacies across the United States, as a shortage of Mylan NV's EpiPen emergency allergy shot drags on due to manufacturing problems.

Novartis' Sandoz unit launched the Symjepi epinephrine shots for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner.

The Swiss drugmaker has an exclusive agreement with Adamis Pharmaceuticals Corp to distribute and commercialize Symjepi in the United States.

Novartis said both the adult and pediatric doses of Symjepi would be immediately available in local US pharmacies.

The wholesale price for a two-pack of adult-dose syringes is $250, Novartis said, below the $300 charged by Mylan for its authorized generic and for Teva's generic version of the EpiPen auto-injector.

Mylan still dominates the market for emergency allergy shots with its EpiPen that delivers a dose of epinephrine in the event of severe, potentially life-threatening allergic reactions to a number of triggers, including bee stings or peanuts.

But there has been a shortage of EpiPens in North America, Europe and Canada due to manufacturing delays. The US Food and Drug Administration added the treatment to its list of drugs in shortage more than a year ago, and it remains on that list.

Teva has built significant market share with its generic this year, reaching 18% of the market in late June, according to a research note from Leerink that cited IQVIA prescription volume data.

Teva said in May it expected to reach around 20% market share by the end of the second quarter and could approach 50% market share by the end of the year.

Copyright Reuters, 2019

Comments

Comments are closed.